Kura Oncology to Present AML Data at ASH Annual Meeting.

miércoles, 3 de diciembre de 2025, 8:38 am ET1 min de lectura
KURA--

Kura Oncology will host a virtual analyst and investor event on December 8, 2025, to discuss data on the triplet combination of ziftomenib with venetoclax and azacitidine in acute myeloid leukemia scheduled for presentation at the ASH Annual Meeting. The event will feature management team members and lead investigators.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios